Versanis Bio scores $70m Series A

Versanis Bio, a developer of medicines that address medical conditions prevalent in older adults, has secured $70 million in Series A financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this